Cargando…

Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease

AIM: To identify a panel of biomarkers that can distinguish between non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and explore molecular mechanism involved in the process of developing NASH from NAFLD. METHODS: Biomarkers may differ during stages of NAFLD. Urine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Shu, Zhan, Zong-Ying, Cao, Hong-Yan, Wu, Chao, Bian, Yan-Qin, Li, Jian-Yuan, Cheng, Gen-Hong, Liu, Ping, Sun, Ming-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Clinical Trials Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403757/ https://www.ncbi.nlm.nih.gov/pubmed/28487615 http://dx.doi.org/10.3748/wjg.v23.i15.2771

Ejemplares similares

Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
por: Mowry, Christopher J., et al.
Publicado: (2021)

2544: Dietary polyunsaturated fatty acid consumption is associated with improved body composition in nonalcoholic steatohepatitis patients
por: Billingsley, Hayley, et al.
Publicado: (2018)

Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
por: Nadinskaia, Maria, et al.
Publicado: (2021)

Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease
por: Tokushige, Katsutoshi, et al.
Publicado: (2013)

Serum metabolomic analysis of the effect of exercise on nonalcoholic fatty liver disease
por: Li, Jia, et al.
Publicado: (2019)

Serum metabolome alterations in patients with early nonalcoholic fatty liver disease
por: Wang, Xuemei, et al.
Publicado: (2022)

Recent advances in nonalcoholic fatty liver disease metabolomics
por: Kim, Hwi Young
Publicado: (2021)

The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease
por: Zhang, Shujun, et al.
Publicado: (2017)

Adiposity, metabolomic biomarkers, and risk of nonalcoholic fatty liver disease: a case-cohort study
por: Pang, Yuanjie, et al.
Publicado: (2021)

Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development
por: Xu, Yan, et al.
Publicado: (2019)

Global metabolomics reveals potential urinary biomarkers of esophageal squamous cell carcinoma for diagnosis and staging
por: Xu, Jing, et al.
Publicado: (2016)

Nonalcoholic fatty liver disease: Diagnostic biomarkers
por: Hadizadeh, Fatemeh, et al.
Publicado: (2017)

NMR-based metabolomic techniques identify potential urinary biomarkers for early colorectal cancer detection
por: Wang, Zhening, et al.
Publicado: (2017)

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
por: Ohno, S., et al.
Publicado: (2013)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Identifying potential biomarkers of nonalcoholic fatty liver disease via genome-wide analysis of copy number variation
por: Li, Yang fan, et al.
Publicado: (2021)

Identification of key genes and pathways in mild and severe nonalcoholic fatty liver disease by integrative analysis
por: Feng, Jin, et al.
Publicado: (2021)

ISCHEMIA Trial: Key Questions and Answers
por: Lopez-Sendon, Jose, et al.
Publicado: (2021)

Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease
por: Wang, Xue-Kai, et al.
Publicado: (2021)

Diagnostic accuracy, clinical utility and influence on decision‐making of a methylation urine biomarker test in the surveillance of non‐muscle‐invasive bladder cancer
por: D'Andrea, David, et al.
Publicado: (2019)

New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial
por: Jeong, Jae Yoon, et al.
Publicado: (2017)

Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease
por: Jayasekera, Dulshan, et al.
Publicado: (2023)

Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease
por: Gîlcă-Blanariu, Georgiana-Emmanuela, et al.
Publicado: (2023)

Untargeted metabolomics characteristics of nonobese nonalcoholic fatty liver disease induced by high-temperature-processed feed in Sprague-Dawley rats
por: Xue, Li-Jun, et al.
Publicado: (2020)

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics
por: He, Xuyun, et al.
Publicado: (2016)

Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease
por: Li, Hu, et al.
Publicado: (2022)

Associations of Urinary Phytoestrogen Concentrations with Nonalcoholic Fatty Liver Disease among Adults
por: Xiong, Guang, et al.
Publicado: (2022)

Identification of key genes associated with poor prognosis and neoplasm staging in gastric cancer
por: Wang, Shuoshan, et al.
Publicado: (2023)

Comparative Analysis Reveals Novel Changes in Plasma Metabolites and Metabolomic Networks of Infants With Retinopathy of Prematurity
por: Yang, Yuhang, et al.
Publicado: (2022)

PIN1, a perspective on genetic biomarker for nonalcoholic fatty liver disease (NAFLD)
por: Wang, Jing-Zhang, et al.
Publicado: (2019)

Ferroptosis resistance cooperates with cellular senescence in the overt stage of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
por: Vetuschi, Antonella, et al.
Publicado: (2022)

Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity
por: Pirola, Carlos J, et al.
Publicado: (2018)

Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease
por: Jiang, Hua, et al.
Publicado: (2023)

Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives
por: Gitto, Stefano, et al.
Publicado: (2018)

Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice
por: Tu, Lan N., et al.
Publicado: (2017)

Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease
por: Ma, Yuanqiang, et al.
Publicado: (2021)

Prolactin is a Key Factor for Nonalcoholic Fatty Liver Disease in Obese Children
por: Zhang, Jianwei, et al.
Publicado: (2023)

SATURN: A European, Prospective, Multicentre Registry for Male Stress Urinary Incontinence Surgery
por: Martens, Frank, et al.
Publicado: (2023)

Cadmium promotes nonalcoholic fatty liver disease by inhibiting intercellular mitochondrial transfer
por: Sun, Jian, et al.
Publicado: (2023)

Identifying therapeutic biomarkers of zoledronic acid by metabolomics
por: Li, Xiang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b0umftp7bqjk06fvkh5264qct5